Erlotinib Completed Phase 1 Trials for Refractory Solid Tumors Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00759928PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors